DE69902396T2 - Stabilisierte flüssige arzneizubereitungen enthaltend botulinum toxin - Google Patents

Stabilisierte flüssige arzneizubereitungen enthaltend botulinum toxin

Info

Publication number
DE69902396T2
DE69902396T2 DE69902396T DE69902396T DE69902396T2 DE 69902396 T2 DE69902396 T2 DE 69902396T2 DE 69902396 T DE69902396 T DE 69902396T DE 69902396 T DE69902396 T DE 69902396T DE 69902396 T2 DE69902396 T2 DE 69902396T2
Authority
DE
Germany
Prior art keywords
botulinum toxin
preparations containing
liquid drug
stabilized liquid
drug preparations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69902396T
Other languages
English (en)
Other versions
DE69902396T3 (de
DE69902396D1 (de
Inventor
Elizabeth Moyer
Pamela Hirtzer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SOLSTICE NEUROSCIENCES, INC., SAN DIEGO, CALIF., U
Original Assignee
Elan Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22277018&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69902396(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Elan Pharmaceuticals LLC filed Critical Elan Pharmaceuticals LLC
Publication of DE69902396D1 publication Critical patent/DE69902396D1/de
Application granted granted Critical
Publication of DE69902396T2 publication Critical patent/DE69902396T2/de
Publication of DE69902396T3 publication Critical patent/DE69902396T3/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/06—Anti-spasmodics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
DE69902396T 1998-09-11 1999-09-09 Stabilisierte flüssige arzneizubereitungen enthaltend botulinum toxin Expired - Lifetime DE69902396T3 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9987098P 1998-09-11 1998-09-11
US99870P 1998-09-11
PCT/US1999/020912 WO2000015245A2 (en) 1998-09-11 1999-09-09 Stable liquid formulations of botulinum toxin

Publications (3)

Publication Number Publication Date
DE69902396D1 DE69902396D1 (de) 2002-09-05
DE69902396T2 true DE69902396T2 (de) 2003-03-20
DE69902396T3 DE69902396T3 (de) 2010-09-30

Family

ID=22277018

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69902396T Expired - Lifetime DE69902396T3 (de) 1998-09-11 1999-09-09 Stabilisierte flüssige arzneizubereitungen enthaltend botulinum toxin

Country Status (41)

Country Link
US (2) US7211261B1 (de)
EP (1) EP1112082B2 (de)
JP (4) JP4557426B2 (de)
KR (1) KR100699756B1 (de)
CN (1) CN100438905C (de)
AP (1) AP1591A (de)
AR (1) AR022671A1 (de)
AT (1) ATE221386T1 (de)
AU (1) AU755556C (de)
BG (1) BG65555B1 (de)
BR (1) BR9913585A (de)
CA (1) CA2342243C (de)
CO (1) CO5170497A1 (de)
CU (1) CU23251A3 (de)
DE (1) DE69902396T3 (de)
DK (1) DK1112082T4 (de)
EA (1) EA003367B1 (de)
EE (1) EE200100140A (de)
ES (1) ES2181473T5 (de)
GE (1) GEP20032946B (de)
HK (1) HK1040927A1 (de)
HR (1) HRP20010259B1 (de)
HU (1) HUP0103638A3 (de)
ID (1) ID28824A (de)
IL (2) IL141564A0 (de)
IS (1) IS2381B (de)
LT (1) LT4959B (de)
LV (1) LV12684B (de)
NO (1) NO328898B1 (de)
NZ (1) NZ509349A (de)
PL (1) PL200926B1 (de)
PT (1) PT1112082E (de)
RS (1) RS50344B (de)
SA (1) SA99200566B1 (de)
SI (2) SI20566B (de)
SK (1) SK286919B6 (de)
TR (1) TR200100728T2 (de)
TW (1) TW574036B (de)
UA (1) UA72477C2 (de)
WO (1) WO2000015245A2 (de)
ZA (1) ZA200101709B (de)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3066079B2 (ja) * 1994-05-09 2000-07-17 ビンダー，ウィリアム，ジェイ． 頭痛を低減する方法
TW574036B (en) * 1998-09-11 2004-02-01 Elan Pharm Inc Stable liquid compositions of botulinum toxin
US20120238504A1 (en) * 1998-09-11 2012-09-20 Solstice Neurosciences, Llc Stable Formulations of Botulinum Toxin in Hydrogels
DE19925739A1 (de) * 1999-06-07 2000-12-21 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Therapeutikum mit einem Botulinum-Neurotoxin
US7838007B2 (en) 1999-12-07 2010-11-23 Allergan, Inc. Methods for treating mammary gland disorders
US7838008B2 (en) 1999-12-07 2010-11-23 Allergan, Inc. Methods for treating diverse cancers
EP1586329A1 (de) * 2000-02-08 2005-10-19 Allergan, Inc. Pharmazeutische Zusammensetzungen mit botulinum Toxin
US20030118598A1 (en) 2000-02-08 2003-06-26 Allergan, Inc. Clostridial toxin pharmaceutical compositions
US8632785B2 (en) * 2000-02-08 2014-01-21 Allergan, Inc. Clostridial toxin pharmaceutical composition containing a gelatin fragment
US20060269575A1 (en) * 2000-02-08 2006-11-30 Allergan, Inc. Botulinum toxin pharmaceutical compositions formulated with recombinant albumin
US7780967B2 (en) 2000-02-08 2010-08-24 Allergan, Inc. Reduced toxicity Clostridial toxin pharmaceutical compositions
US6821520B2 (en) 2000-02-15 2004-11-23 Allergan, Inc. Clostridial toxin therapy for Hashimoto's thyroiditis
ITUD20010002A1 (it) 2001-01-05 2002-07-05 Univ Degli Studi Udine Uso della tossina botulinica per la soluzione di patologie articolari, in particolare della coxartrosi, della epicondilite e della patolo
CA2369810C (en) * 2002-01-30 2007-08-07 1474791 Ontario Limited Method of treating pain
US7140371B2 (en) 2002-03-14 2006-11-28 Allergan, Inc. Surface topography method for determining effects of a botulinum toxin upon a muscle and for comparing botulinum toxins
US6688311B2 (en) 2002-03-14 2004-02-10 Allergan, Inc. Method for determining effect of a clostridial toxin upon a muscle
EP1491205A4 (de) * 2002-03-29 2007-04-25 Chemo Sero Therapeut Res Inst Mittel zur behandlung von hypermyotonie
US7691394B2 (en) * 2002-05-28 2010-04-06 Botulinum Toxin Research Associates, Inc. High-potency botulinum toxin formulations
US20040009180A1 (en) * 2002-07-11 2004-01-15 Allergan, Inc. Transdermal botulinum toxin compositions
CA2854831C (en) 2002-11-21 2016-08-30 Ira Sanders Treatment of mammalian reaction to ige interactions
MXPA05006690A (es) * 2002-12-20 2006-02-17 Botulinum Toxin Res Ass Inc Composiciones farmaceuticas de toxina botulinica mejoradas.
US8071550B2 (en) 2003-03-03 2011-12-06 Allergan, Inc. Methods for treating uterine disorders
MXPA05009425A (es) * 2003-03-06 2006-02-10 Botulinum Toxin Res Ass Inc Tratamiento del dolor facial cronico y cefalea relacionados con la sinusitis con toxina botulinica.
WO2004078200A1 (en) * 2003-03-06 2004-09-16 Botulinum Toxin Research Associates, Inc. Selection of patients with increased responsiveness to botulinum toxin
US6838434B2 (en) * 2003-05-02 2005-01-04 Allergan, Inc. Methods for treating sinus headache
US7220422B2 (en) * 2003-05-20 2007-05-22 Allergan, Inc. Methods and compositions for treating eye disorders
US8617572B2 (en) 2003-10-29 2013-12-31 Allergan, Inc. Botulinum toxin treatments of depression
US8734810B2 (en) 2003-10-29 2014-05-27 Allergan, Inc. Botulinum toxin treatments of neurological and neuropsychiatric disorders
US8609113B2 (en) 2003-10-29 2013-12-17 Allergan, Inc. Botulinum toxin treatments of depression
US8609112B2 (en) 2003-10-29 2013-12-17 Allergan, Inc. Botulinum toxin treatments of depression
AU2005251676B2 (en) 2004-03-03 2011-09-29 Revance Therapeutics, Inc. Compositions and methods for topical diagnostic and therapeutic transport
PT2656859E (pt) 2004-03-03 2016-02-24 Revance Therapeutics Inc Aplicação tópica e administração transdérmica de toxinas botulínicas
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
KR100852822B1 (ko) 2004-07-26 2008-08-18 메르츠 파마 게엠베하 운트 코. 카가아 보툴리눔 신경독소를 포함하는 치료 조성물
US7179474B2 (en) 2004-09-03 2007-02-20 Allergan, Inc. Methods for treating a buttock deformity
US7429386B2 (en) 2004-09-03 2008-09-30 Allergan, Inc. Stretch mark treatment
WO2006073410A1 (en) * 2005-01-03 2006-07-13 Botulinum Toxin Research Associates, Inc. Compositions, methods and devices for preparing less painful botulinum toxin formulations
US9180081B2 (en) 2005-03-03 2015-11-10 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
US7419675B2 (en) 2005-05-26 2008-09-02 Allergan, Inc. Method for treating peritoneal adhesions
US8323666B2 (en) 2005-08-01 2012-12-04 Allergan, Inc. Botulinum toxin compositions
US8137677B2 (en) 2005-10-06 2012-03-20 Allergan, Inc. Non-protein stabilized clostridial toxin pharmaceutical compositions
US8168206B1 (en) 2005-10-06 2012-05-01 Allergan, Inc. Animal protein-free pharmaceutical compositions
DE102006019447A1 (de) * 2006-04-24 2007-10-25 Dressler, Dirk, Dr. Markierung von Botulinum Toxin
AR061669A1 (es) 2006-06-29 2008-09-10 Merz Pharma Gmbh & Co Kgaa Aplicacion de alta frecuencia de terapia con toxina botulinica
US10792344B2 (en) 2006-06-29 2020-10-06 Merz Pharma Gmbh & Co. Kgaa High frequency application of botulinum toxin therapy
JP2010529000A (ja) * 2007-06-01 2010-08-26 メルツ・ファルマ・ゲーエムベーハー・ウント・コ・カーゲーアーアー ボツリヌス毒素の神経毒成分をベースにした温度に安定な筋弛緩薬の提供方法
EP2048156A1 (de) * 2007-10-12 2009-04-15 Merz Pharma GmbH & Co.KGaA Prozess zur Bereitstellung eines temperaturstabilen Muskelrelaxans auf der Basis der neurotoxischen Komponente von Botulintoxin
US9107815B2 (en) 2008-02-22 2015-08-18 Allergan, Inc. Sustained release poloxamer containing pharmaceutical compositions
US20170361130A9 (en) * 2008-05-23 2017-12-21 Pankaj Modi Stabilized and solubilized drug formulation for topical application and transdermal efficacy for cosmetic improvement and methods of formulation
WO2010016901A1 (en) * 2008-08-05 2010-02-11 Solstice Neurosciences, Inc. Compositions of activated botulinum holotoxin type b (150 kd)
EP2315598A1 (de) * 2008-08-05 2011-05-04 Solstice Neurosciences, Inc. Zusammensetzungen aus aktiviertem botulintoxin vom typ b
US20100112006A1 (en) * 2008-11-03 2010-05-06 Solstice Neurosciences, Inc. Compositions of activated botulinum holotoxin type B (150 kD)
WO2010051039A1 (en) * 2008-11-03 2010-05-06 Solstice Neurosciences, Inc. Compositions of activated botulinum toxin type b
US20100124559A1 (en) * 2008-11-20 2010-05-20 Allergan, Inc. Early Treatment and Prevention of Increased Muscle Tonicity
EP2364168A1 (de) 2008-12-04 2011-09-14 Botulinum Toxin Research Associates, Inc. Verlängerte botulinustoxin-formulierung zur anwendung bei menschen oder säugetieren
BRPI0923731B1 (pt) 2008-12-31 2024-02-06 Revance Therapeutics, Inc Composições para uso em um método não-terapêutico de administração de toxina botulínica, seus usos e método de preparação
EP2248518B1 (de) * 2009-04-17 2013-01-16 Merz Pharma GmbH & Co. KGaA Formulierung zur Stabilisierung von Proteinen, Peptiden und deren Mischungen.
CN102869373B (zh) 2009-06-25 2017-05-10 雷文斯治疗公司 不含白蛋白的肉毒杆菌毒素制剂
IN2012DN00733A (de) 2009-07-02 2015-06-19 Merz Pharma Gmbh & Co Kgaa
BR112012009227A2 (pt) 2009-10-21 2016-08-23 Revance Therapeutics Inc métodos e sistemas para purificar neurotoxina botulínica não complexada
AU2012209274A1 (en) * 2011-01-24 2013-09-12 Anterios, Inc. Nanoparticle compositions, formulations thereof, and uses therefor
RU2646110C2 (ru) 2011-11-09 2018-03-01 Мерц Фарма Гмбх Унд Ко. Кгаа Нейротоксины, проявляющие укороченную биологическую активность
US9393291B2 (en) 2012-04-12 2016-07-19 Botulinum Toxin Research Associates, Inc. Use of botulinum toxin for the treatment of cerebrovascular disease, renovascular and retinovascular circulatory beds
MX370929B (es) 2012-10-28 2020-01-08 Revance Therapeutics Inc Composiciones y usos de las mismas para el tratamiento seguro de la rinitis.
RU2535115C1 (ru) * 2013-05-15 2014-12-10 Бости Трейдинг Лтд Фармацевтический состав, содержащий нейротоксин ботулина
US11484580B2 (en) 2014-07-18 2022-11-01 Revance Therapeutics, Inc. Topical ocular preparation of botulinum toxin for use in ocular surface disease
US9901627B2 (en) 2014-07-18 2018-02-27 Revance Therapeutics, Inc. Topical ocular preparation of botulinum toxin for use in ocular surface disease
WO2016036618A1 (en) * 2014-09-02 2016-03-10 American Silver, Llc Botulinum toxin and colloidal silver particles
AU2015371726B2 (en) * 2014-12-23 2020-10-22 Merz Pharma Gmbh & Co. Kgaa Botulinum toxin prefilled container
SG11201706247VA (en) 2015-02-03 2017-08-30 Merz Pharma Gmbh & Co Kgaa Botulinum toxin prefilled container
JP7053498B2 (ja) * 2016-05-27 2022-04-12 ガルデルマ・ホールディング・エスアー トリプトファンまたはチロシンで安定化された液体神経毒素製剤
WO2018038301A1 (en) * 2016-08-26 2018-03-01 Hugel Inc. Stabilized liquid formulation of botulinum toxin and preparation method thereof
TW202247855A (zh) 2016-09-13 2022-12-16 美商愛力根公司 非蛋白梭菌毒素組成物
CN110198703A (zh) 2016-11-21 2019-09-03 艾里奥治疗公司 大试剂的透皮递送
KR101744900B1 (ko) * 2017-01-20 2017-06-08 주식회사 대웅 보툴리눔 독소를 포함하는 안정한 액상 조성물
KR20200006587A (ko) * 2017-05-18 2020-01-20 레반스 테라퓨틱스, 아이엔씨. 경부 근긴장이상증의 치료 방법
KR102063475B1 (ko) 2018-02-22 2020-01-09 주식회사 에이비바이오 보툴리눔 독소, 안정화제, 및 국소마취제를 포함하는 액상 제형 및 이의 제조방법
WO2020074419A1 (en) 2018-10-08 2020-04-16 Merz Pharma Gmbh & Co. Kgaa Neurotoxin prefilled vial

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3522247A (en) * 1967-11-07 1970-07-28 Pfizer & Co C 2-amino-6,7-disubstituted-4h-1,3-benzothiazine-4-ones as bronchodilators
US4932936A (en) 1988-01-29 1990-06-12 Regents Of The University Of Minnesota Method and device for pharmacological control of spasticity
US5053005A (en) 1989-04-21 1991-10-01 Gary E. Borodic Chemomodulation of curvature of the juvenile spine
US5919665A (en) * 1989-10-31 1999-07-06 Ophidian Pharmaceuticals, Inc. Vaccine for clostridium botulinum neurotoxin
US5183462A (en) * 1990-08-21 1993-02-02 Associated Synapse Biologics Controlled administration of chemodenervating pharmaceuticals
GB9120306D0 (en) 1991-09-24 1991-11-06 Graham Herbert K Method and compositions for the treatment of cerebral palsy
AU4646393A (en) * 1992-06-23 1994-01-24 Interactive Biologics Associates Pharmaceutical composition containing botulinum b complex
JPH06192118A (ja) * 1992-09-28 1994-07-12 Wisconsin Alumni Res Found ボツリヌス毒素を含む異常に過敏な筋運動障害の治療用薬剤組成物およびその製造方法
AU683275B2 (en) 1993-06-10 1997-11-06 Allergan, Inc. Multiple botulinum toxins for treating neuromuscular disorders and conditions
EP0702561B1 (de) 1993-06-10 2002-01-09 Allergan, Inc. Behandlung von neuromusculaeren stoerungen und zustaenden mit botulism serotyp e
GB9315306D0 (en) 1993-07-23 1993-09-08 Smithkline Beecham Corp Methods
US5437291A (en) 1993-08-26 1995-08-01 Univ Johns Hopkins Method for treating gastrointestinal muscle disorders and other smooth muscle dysfunction
US6974578B1 (en) * 1993-12-28 2005-12-13 Allergan, Inc. Method for treating secretions and glands using botulinum toxin
DE69434610T2 (de) 1993-12-28 2008-11-27 Allergan, Inc., Irvine Verwendung der neurotoxischen Komponente des Botulinum Toxins zur Behandlung von Muskelspasmen
US5766605A (en) 1994-04-15 1998-06-16 Mount Sinai School Of Medicine Of The City University Of New York Treatment of autonomic nerve dysfunction with botulinum toxin
JP3066079B2 (ja) 1994-05-09 2000-07-17 ビンダー，ウィリアム，ジェイ． 頭痛を低減する方法
AU2907695A (en) * 1994-08-08 1996-03-07 Wisconsin Alumni Research Foundation Purification and pharmaceutical compositions containing type g botulinum neurotoxin
US5512547A (en) * 1994-10-13 1996-04-30 Wisconsin Alumni Research Foundation Pharmaceutical composition of botulinum neurotoxin and method of preparation
US5756468A (en) * 1994-10-13 1998-05-26 Wisconsin Alumni Research Foundation Pharmaceutical compositions of botulinum toxin or botulinum neurotoxin and methods of preparation
US5562899A (en) 1995-02-28 1996-10-08 Gerber; Allen Medical prevention of lacerations to the vagina and perineum
US6136551A (en) * 1995-04-24 2000-10-24 Allergan, Inc. Assay for detecting the presence of botulinum toxin neutralizing antibodies in a patient serum sample
DK0773788T3 (da) 1995-06-06 2003-09-01 Allergan Inc Forbedrede præparater og fremgangsmåder til kemodenervering under anvendelse af neurotoxiner
US5721215A (en) 1996-03-20 1998-02-24 Allergan Injectable therapy for control of muscle spasms and pain related to muscle spasms
US6699966B1 (en) * 1996-07-08 2004-03-02 University Of Massachusetts Proteins within the type E botulinum neurotoxin complex
CN1057430C (zh) * 1996-10-09 2000-10-18 崔生发 一种生物化学杀鼠剂
TW574036B (en) * 1998-09-11 2004-02-01 Elan Pharm Inc Stable liquid compositions of botulinum toxin
US6146902A (en) * 1998-12-29 2000-11-14 Aventis Pasteur, Inc. Purification of polysaccharide-protein conjugate vaccines by ultrafiltration with ammonium sulfate solutions
US6113915A (en) 1999-10-12 2000-09-05 Allergan Sales, Inc. Methods for treating pain
US6139845A (en) 1999-12-07 2000-10-31 Allergan Sales, Inc. Method for treating cancer with a neurotoxin
US20030118598A1 (en) * 2000-02-08 2003-06-26 Allergan, Inc. Clostridial toxin pharmaceutical compositions
EP1586329A1 (de) * 2000-02-08 2005-10-19 Allergan, Inc. Pharmazeutische Zusammensetzungen mit botulinum Toxin
US6358513B1 (en) 2000-02-15 2002-03-19 Allergan Sales, Inc. Method for treating Hashimoto's thyroiditis
US6464986B1 (en) * 2000-04-14 2002-10-15 Allegan Sales, Inc. Method for treating pain by peripheral administration of a neurotoxin
WO2006096164A1 (en) * 2005-03-03 2006-09-14 Allergan, Inc. Media for clostridium bacterium and processes for obtaining a clostridial toxin
US20080096238A1 (en) * 2004-03-30 2008-04-24 Alcon, Inc. High throughput assay for human rho kinase activity with enhanced signal-to-noise ratio
WO2006101809A1 (en) 2005-03-15 2006-09-28 Allergan, Inc. Modified clostridial toxins with enhanced targeting capabilities for endogenous clostridial toxin receptor systems
US7855268B2 (en) * 2006-06-01 2010-12-21 Allergan, Inc. Tolerogizing compositions comprising botulinum toxin type B peptides

Also Published As

Publication number Publication date
US8173138B2 (en) 2012-05-08
HUP0103638A2 (hu) 2002-01-28
SI20566B (sl) 2008-08-31
JP5270594B2 (ja) 2013-08-21
ID28824A (id) 2001-07-05
JP2002524527A (ja) 2002-08-06
HRP20010259B1 (en) 2007-11-30
HRP20010259A2 (en) 2005-02-28
KR100699756B1 (ko) 2007-03-27
TR200100728T2 (tr) 2001-08-21
BR9913585A (pt) 2001-06-05
DK1112082T3 (da) 2002-11-25
PT1112082E (pt) 2002-12-31
AU755556B2 (en) 2002-12-12
CA2342243C (en) 2014-01-14
NO328898B1 (no) 2010-06-07
LT2001041A (en) 2002-06-25
JP4557426B2 (ja) 2010-10-06
PL200926B1 (pl) 2009-02-27
CO5170497A1 (es) 2002-06-27
US20070148189A1 (en) 2007-06-28
DE69902396T3 (de) 2010-09-30
AR022671A1 (es) 2002-09-04
UA72477C2 (uk) 2005-03-15
NZ509349A (en) 2003-08-29
CN1316906A (zh) 2001-10-10
CN100438905C (zh) 2008-12-03
LV12684A (en) 2001-07-20
DK1112082T4 (da) 2010-05-31
SI1112082T1 (en) 2002-12-31
BG105435A (en) 2001-12-29
KR20010086388A (ko) 2001-09-10
ES2181473T5 (es) 2010-07-05
NO20011207L (no) 2001-05-09
CU23251A3 (es) 2007-12-17
IS5836A (is) 2001-01-31
SI20566A (sl) 2001-12-31
TW574036B (en) 2004-02-01
HK1040927A1 (en) 2002-06-28
HUP0103638A3 (en) 2004-06-28
EA003367B1 (ru) 2003-04-24
US7211261B1 (en) 2007-05-01
JP2010138186A (ja) 2010-06-24
JP2007169301A (ja) 2007-07-05
WO2000015245A2 (en) 2000-03-23
WO2000015245A3 (en) 2000-06-08
IS2381B (is) 2008-07-15
DE69902396D1 (de) 2002-09-05
AP1591A (en) 2006-03-20
ES2181473T3 (es) 2003-02-16
EP1112082A2 (de) 2001-07-04
NO20011207D0 (no) 2001-03-09
EA200100337A1 (ru) 2001-10-22
IL141564A (en) 2009-08-03
GEP20032946B (en) 2003-04-25
YU19001A (sh) 2005-06-10
EP1112082B2 (de) 2010-03-17
EP1112082B1 (de) 2002-07-31
EE200100140A (et) 2002-06-17
SK3132001A3 (en) 2001-10-08
JP2013144691A (ja) 2013-07-25
LV12684B (lv) 2001-10-20
SA99200566B1 (ar) 2006-09-20
AU5821499A (en) 2000-04-03
AP2001002108A0 (en) 2001-03-31
ZA200101709B (en) 2002-11-28
LT4959B (lt) 2002-10-25
IL141564A0 (en) 2002-03-10
BG65555B1 (bg) 2008-12-30
SK286919B6 (sk) 2009-07-06
PL347069A1 (en) 2002-03-11
RS50344B (sr) 2009-11-10
CA2342243A1 (en) 2000-03-23
AU755556C (en) 2005-12-15
ATE221386T1 (de) 2002-08-15

Similar Documents

Publication Publication Date Title
DE69902396D1 (de) Stabilisierte flüssige arzneizubereitungen enthaltend botulinum toxin
DE69831620D1 (de) Arzneizubereitungen enthaltend Kannabinoide
DE122010000011I1 (de) Flüssige gonadotropinhaltige Arzneimittel
IS5953A (is) Lyfjablöndur úr örgerðum eplerenonum
DK0981375T3 (da) Farmaceutiske præparater indeholdende plasmaprotein
NO20021401D0 (no) Konazolinforbindelser og farmasöytiske preparater inneholdende slike forbindelser
DE69814091D1 (de) Voriconazol-enthaltende pharmazeutische zubereitungen
DE69800639T2 (de) Tetrahydrolipstatin enthaltende präparate
DK1035771T3 (da) Tensidsystemer til flydende vandige præparater
ATE265852T1 (de) Geschmackskaschierte flüssige arzneizubereitungen
DK0988861T3 (da) Stabiliserede proteinpræparater
ATE332132T1 (de) Verbesserte arzneizubereitungen enthaltend ritonavir
NO20015711D0 (no) Farmasöytiske preparater inneholdende anti-Fas-antistoff
DK0925273T3 (da) Farmaceutiske præparater indeholdende 4-oxo-butansyrer
DE69926012D1 (de) Arzneizubereitungen
NO995838D0 (no) Nye heteroetynylenforbindelser og farmasöytiske og kosmetiske preparater inneholdende de samme
DK1041966T3 (da) Farmaceutiske præparater omfattende zafirlukast
PT1077684E (pt) Preparacoes efervescentes
EE9800275A (et) Misolastiini sisaldavad prolongeeritud toimega farmatseutilised preparaadid
DE69906934D1 (de) Arzneizubereitungen
DE69904021T2 (de) Flüsige pharmazeusche zubereitung enthaltend zotepin
DK0859635T3 (da) Stabiliserede farmaceutiske præparater indeholdende dobutamin
GB9502133D0 (en) Pharmaceutical composition containing botulinum neurotoxin

Legal Events

Date Code Title Description
8363 Opposition against the patent
8327 Change in the person/name/address of the patent owner

Owner name: SOLSTICE NEUROSCIENCES, INC., SAN DIEGO, CALIF., U

8366 Restricted maintained after opposition proceedings
8328 Change in the person/name/address of the agent

Representative=s name: VOSSIUS & PARTNER, 81675 MUENCHEN